<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04480736</url>
  </required_header>
  <id_info>
    <org_study_id>CR108700</org_study_id>
    <secondary_id>64281802DNG2001</secondary_id>
    <nct_id>NCT04480736</nct_id>
  </id_info>
  <brief_title>A Study of JNJ-64281802 Against Dengue Serotype 1 Infection in a Dengue Human Challenge Model in Healthy Adult Participants</brief_title>
  <official_title>A Phase 2a, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of Repeated Oral Doses of JNJ-64281802 Against Dengue Serotype 1 Infection in a Dengue Human Challenge Model in Healthy Adult Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the antiviral activity of JNJ-64281802 versus placebo
      in terms of reduction of dengue virus 1 (DENV-1) ribonucleic acid (RNA) viral load (VL).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 20, 2020</start_date>
  <completion_date type="Anticipated">June 9, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 9, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the DENV-1 RNA VL-concentration time Curve (VL AUC) from Immediately before Inoculation (Baseline on Day 1) until Day 29</measure>
    <time_frame>Baseline to Day 29</time_frame>
    <description>Area under the dengue virus (DENV)-1 ribonucleic acid (RNA) Viral Load (VL) concentration-time curves from immediately before inoculation (baseline on Day 1) until Day 29 will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability</measure>
    <time_frame>Up to Day 85</time_frame>
    <description>An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Abnormalities in Physical Examination</measure>
    <time_frame>Up to Day 85</time_frame>
    <description>Number of participants with clinically significant abnormalities in physical examination will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Abnormalities in Vital Signs</measure>
    <time_frame>Up to Day 85</time_frame>
    <description>Number of participants with clinically significant abnormalities in vital signs (body temperature, pulse/heart rate, systolic and diastolic blood pressure) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Abnormalities in Electrocardiogram (ECGs)</measure>
    <time_frame>Up to Day 70</time_frame>
    <description>Number of participants with clinically significant abnormalities in electrocardiogram (ECGs) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Abnormalities in Laboratory Parameters</measure>
    <time_frame>Up to Day 85</time_frame>
    <description>Number of participants with clinically significant abnormalities in laboratory parameters (serum chemistry, hematology, blood coagulation, and urine samples) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with DENV Infection Associated AEs</measure>
    <time_frame>Up to Day 85</time_frame>
    <description>Number of participants with DENV infection associated AEs will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the log10-transformed DENV 1 RNA VL Concentration-time Curves from Immediately before Inoculation (Baseline on Day 1) until Day 29</measure>
    <time_frame>Baseline to Day 29</time_frame>
    <description>Area under the log10-transformed DENV 1 RNA VL concentration-time curves from immediately before inoculation (baseline on Day 1) until Day 29 will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak of Detectable DENV-1 RNA</measure>
    <time_frame>Up to Day 85</time_frame>
    <description>Peak of detectable DENV-1 RNA will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Detectable DENV-1 RNA</measure>
    <time_frame>Up to Day 85</time_frame>
    <description>Duration of detectable DENV-1 RNA will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Onset of Detectable DENV-1 RNA</measure>
    <time_frame>Up to Day 85</time_frame>
    <description>Time to first onset of detectable DENV-1 RNA will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Detectable DENV-1 RNA</measure>
    <time_frame>Up to Day 85</time_frame>
    <description>Number of participants with detectable DENV-1 RNA will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Viremia Curves from Immediately before Inoculation (Baseline on Day 1) until Day 29</measure>
    <time_frame>Baseline to Day 29</time_frame>
    <description>Area under the viremia curves from immediately before inoculation (baseline on Day 1) until Day 29 will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the log10-transformed Viremia Curves</measure>
    <time_frame>Up to Day 85</time_frame>
    <description>Area under the log10-transformed viremia curves will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak of Detectable Viremia Level</measure>
    <time_frame>Up to Day 85</time_frame>
    <description>Peak of detectable viremia level will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Detectable Viremia</measure>
    <time_frame>Up to Day 85</time_frame>
    <description>Duration of detectable viremia will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Onset of Detectable Viremia</measure>
    <time_frame>Up to Day 85</time_frame>
    <description>Time to first onset of detectable viremia will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Detectable Viremia</measure>
    <time_frame>Up to Day 85</time_frame>
    <description>Number of participants with detectable viremia will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Analyte Concentration (Cmax) of JNJ-64281802</measure>
    <time_frame>Day -5: Predose, 1, 2, 4, 6, 8, 10, 12 hours Postdose; Day 21: Predose, 1, 2, 4, 6, 8, 12, 24 and 96 hours Postdose</time_frame>
    <description>Cmax is the maximum observed analyte concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Observed Analyte Concentration (Cmin) of JNJ-64281802</measure>
    <time_frame>Day 21: Predose, 1, 2, 4, 6, 8, 12, 24 and 96 hours Postdose</time_frame>
    <description>Cmin is the minimum observed analyte concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Plasma Analyte Concentration (Ctrough) of JNJ-64281802</measure>
    <time_frame>Day -4, 1, 6, 8, 10, and 15: Predose; Day 21: Predose, 1, 2, 4, 6, 8, 12, 24 and 96 hours Postdose</time_frame>
    <description>(Ctrough) is defined as observed analyte concentration just prior to the beginning or at the end of a dosing interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Analyte Concentration (Cavg) of JNJ-64281802</measure>
    <time_frame>Day -5: Predose, 1, 2, 4, 6, 8, 10, 12 hours postdose; Day 21: Predose, 1, 2, 4, 6, 8, 12, 24 and 96 hours Postdose</time_frame>
    <description>Cavg is defined as average analyte concentration over the dosing interval (tau) and will be calculated as AUCtau/Tau.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Analyte Concentration (Tmax) of JNJ-64281802</measure>
    <time_frame>Day -5: Predose, 1, 2, 4, 6, 8, 10, 12 hours postdose; Day 21: Predose, 1, 2, 4, 6, 8, 12, 24 and 96 hours Postdose</time_frame>
    <description>Tmax is defined as the actual sampling time to reach the maximum observed plasma analyte concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluctuation Index (FI) of JNJ-64281802</measure>
    <time_frame>Day 21: Predose, 1, 2, 4, 6, 8, 12, 24 and 96 hours Postdose</time_frame>
    <description>FI is the percentage fluctuation (variation between maximum and minimum concentration at steady state), calculated as: 100*([Cmax-Cmin]/Cavg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve from Time Zero to End of Dosing Interval (AUCtau)</measure>
    <time_frame>Day -5: Predose, 1, 2, 4, 6, 8, 10, 12 hours postdose; Day 21: Predose, 1, 2, 4, 6, 8, 12, 24 and 96 hours Postdose</time_frame>
    <description>The AUCtau is the measure of the plasma analyte concentration from time zero to end of dosing interval. AUC during a dosing interval (Ï„), calculated by linear-linear trapezoidal summation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Anti DENV-1 Total IgM and IgG Antibody Titers</measure>
    <time_frame>Up to Day 85</time_frame>
    <description>Anti-DENV-1 immunoglobulin G (IgG) and immunoglobulin M (IgM) antibodies will be measured using enzyme-linked immunosorbent assay (ELISA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Onset of Anti-DENV-1 Total IgM and IgG Antibody Titers</measure>
    <time_frame>Up to Day 85</time_frame>
    <description>Time to first onset of anti-DENV-1 total IgM and IgG antibody titers will be reported.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">53</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive matching placebo of JNJ-64281802 orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JNJ-64281802 High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive high dose of JNJ-64281802 orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JNJ-64281802 Medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive medium dose of JNJ-64281802 orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JNJ-64281802 Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive low dose of JNJ-64281802 orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JNJ-64281802 Dosing Regimen X</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive dosing regimen X of JNJ-64281802 orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JNJ-64281802 Dosing Regimen Y</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive dosing regimen Y of JNJ-64281802 orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JNJ-64281802 Dosing Regimen Z</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive dosing regimen Z of JNJ-64281802 orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo will be administered orally.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-64281802 High dose</intervention_name>
    <description>JNJ-64281802 high dose will be administered orally.</description>
    <arm_group_label>JNJ-64281802 High dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-64281802 Medium dose</intervention_name>
    <description>JNJ-64281802 medium dose will be administered orally.</description>
    <arm_group_label>JNJ-64281802 Medium dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-64281802 Low dose</intervention_name>
    <description>JNJ-64281802 low dose will be administered orally.</description>
    <arm_group_label>JNJ-64281802 Low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-64281802 Dosing Regimen X</intervention_name>
    <description>JNJ-64281802 dosing regimen X will be administered orally.</description>
    <arm_group_label>JNJ-64281802 Dosing Regimen X</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-64281802 Dosing Regimen Y</intervention_name>
    <description>JNJ-64281802 dosing regimen Y will be administered orally.</description>
    <arm_group_label>JNJ-64281802 Dosing Regimen Y</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-64281802 Dosing Regimen Z</intervention_name>
    <description>JNJ-64281802 dosing regimen Z will be administered orally.</description>
    <arm_group_label>JNJ-64281802 Dosing Regimen Z</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy on the basis of physical examination, medical history, and vital signs
             performed at screening. If there are abnormalities, the participant may be included
             only if the investigator judges the abnormalities to be not clinically relevant. This
             determination must be recorded in the participant's source documents and initialed and
             dated by the investigator

          -  Must pass the comprehension test (i.e., obtain a passing score of greater than or
             equal to (&gt;=) 75 percent (%), with up to 3 attempts in total) indicating that he or
             she understands the purpose, procedures, and potential risks and benefits of the
             study, after reading the informed consent and after the investigator or designee has
             provided detailed information on the study and answered the potential participant's
             questions

          -  Must have a blood pressure (after the participant is supine for &gt;=5 minutes) between
             90 and 140 millimeters of Mercury (mmHg) systolic, extremes included, and less than or
             equal to (&lt;=)90 mmHg diastolic at screening. Two repeat measurements are allowed in
             the absence of any other concerning health screening issues

          -  Must have a Body mass index (BMI) (weight in kilogram divided by the square of height
             in meters) between 18.0 and 30.0 kilogram per meter square (kg/m^2), extremes
             included, and a body weight of &gt;=50.0 kg at screening

          -  All women of childbearing potential must have a negative highly sensitive serum
             (beta-human chorionic gonadotropin) pregnancy test at screening

        Exclusion Criteria:

          -  Known allergies, hypersensitivity, or intolerance to JNJ-64281802 or its excipients,
             to a previous vaccination, or to specific medications/animals for which antigens may
             be in the dengue virus (DENV)-1 challenge strain preparations, including shellfish,
             fetal bovine serum, L-glutamine, neomycin, and streptomycin

          -  Any condition for which, in the opinion of the investigator, participation would not
             be in the best interest of the participant (example, compromise the well-being) or
             that could prevent, limit, or confound the protocol-specified assessments

          -  Received an investigational intervention (including investigational vaccines) or used
             an invasive investigational medical device within 6 months before first dose of study
             drug, or is currently enrolled in an investigational study, or is planning to be
             enrolled in an investigational study within 90 days after last dose of study drug

          -  Pregnant, breastfeeding, or planning to become pregnant during the study or within 90
             days after last dose of study drug

          -  Plans to father a child during the study or within 90 days after last dose of study
             drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 17, 2020</study_first_submitted>
  <study_first_submitted_qc>July 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2020</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dengue</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

